AJMC - Change is Coming

AJMC - Change is Coming

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|March 31, 2025

Tildrakizumab for Nail Psoriasis: Key Findings From AAD 2025

A panelist discusses how new data from the 2025 American Academy of Dermatology Annual Meeting (AAD 2025) demonstrates tildrakizumab’s efficacy in treating nail psoriasis, with the 100-mg dose showing significant improvements in mNAPSI 75 and ViSENPsO responses at week 28 compared with placebo, potentially addressing a critical unmet need in psoriasis treatment.

Episodes in this series

1 expert is featured in this series.

EP. 1 Tildrakizumab for Nail Psoriasis: Key Findings From AAD 2025

1 expert is featured in this series.

EP. 2 AAD 2025 Insights: Treatment Patterns in Moderate to Severe Psoriasis Patients on Biologics

1 expert is featured in this series.

EP. 3 Adherence in Psoriasis Care: Barriers, Solutions, and the Road Ahead

1 expert is featured in this series.

EP. 4 Ruxolitinib Cream and Atopic Dermatitis at AAD 2025

1 expert is featured in this series.

EP. 5 JAK Inhibitors vs Cytokine Inhibitors: AAD 2025 Findings on Infection Risks

1 expert is featured in this series.

EP. 6 From AAD 2025 to the Future: Advancements in Dermatology to Watch

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Global connection concept-S-stock.adobe.com.jpeg

Photobiomodulation, Bio-Machines, and the Future of Dermatology

ByGiuliana Grossi

January 30th 2026

Addressing the Fragmentation of MS Care: Kavita Nair, PhD

ByKavita V. Nair, PhD

January 30th 2026

Glaucoma awareness month | Image credit: khaled - stock.adobe.com

Glaucoma Awareness Month Shines Light on Eye Condition Known as the Silent Thief

ByJulia Bonavitacola,Jullia Rosdahl, MD, PhD,Ariana Levin, MD,Manjool Shah, MD

January 30th 2026

Image credit: Yurii Kibalnik-stock.adobe.com

Combination Therapy, Biologics, and Surgery Redefine HS Care in 2026

ByGiuliana Grossi

January 29th 2026

Manjool Shah, MD

Treatment for Glaucoma Continues to Evolve, Allowing Eye Doctors to Personalize Treatment: Manjool Shah, MD

ByJulia Bonavitacola,Manjool Shah, MD

January 29th 2026

Latest CME

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs

2.0 Credits / General Pharmacy

Trending on AJMC

AI-Supported Mammography Caught More Cancers During Screening

Combination Therapy, Biologics, and Surgery Redefine HS Care in 2026

The Strategic Necessity of Pharma-MedTech Convergence in an Era of Precision Medicine

AAP Breaks With CDC, Maintains Broader 2026 Childhood and Adolescent Vaccine Schedule

CLL Breakthrough: 100% Efficacy Reported for VenR Retreatment

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

© 2025 MJH Life Sciences^®

All rights reserved.